Search "pharma competitive intelligence" in 2026 and you will find a crowded field of platforms, agencies, and one-off consultancies. Most sell one of two things: an expensive subscription dashboard you have to operate yourself, or a bespoke consulting engagement that takes weeks and costs six figures. Neither fits the way commercial teams actually work when a launch clock is running.
What a good CI brief actually contains
A competitive intelligence brief earns its place on your desk when it answers a specific commercial question with primary-sourced evidence. The best briefs share four traits:
- Drug-by-drug commercial posture — not a feature matrix, but a read on how each competitor is actually priced, positioned, and reimbursed.
- Payer and access reality — formulary tier, step-edit logic, and HTA outcomes, because access is where launches are won or lost.
- Primary sourcing — every figure traceable to FDA, PubMed, ClinicalTrials.gov, EMA, NICE, or a live payer policy.
- Deliverables you can present — PDF, Excel, and PowerPoint, ready the day the brief lands.
Where AXLRx fits
AXLRx sits deliberately between the dashboard and the consultancy. You commission the exact indication, comparator set, and market you need. Scope is confirmed within 24 hours and the finished brief is delivered in 72 — built from primary sources, verified against every citation, and shipped as PDF, Excel, and PowerPoint. No subscription, no portal to learn.
How to choose
If your team needs continuous monitoring across dozens of assets, a platform subscription may be right. If you need a defensible answer to one commercial question before a specific decision, a research-verified custom brief will get you there faster and cheaper. Match the tool to the decision, not the other way around.